.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Spotlight

OncClub: Join the Chat on Trending Trials in Cancer
Final results from the Phase 3 ClarIDHy trial
Lively expert panel discussions featuring peer-to-peer exchanges
Long-term efficacy and safety of TRK fusion-positive lung cancer treatment

SpecialtySee All >

Biosimilars
Breast Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Gynecologic Oncology
Head & Neck Cancers
Hematologic Oncology
Immuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Multiple Myeloma

Advertise
About OncLive
Editorial Board
CureToday.com
TargetedOnc.com
CancerNetwork.com
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information

2 Clarke Drive
Suite 100
Cranbury, NJ 08512

2019 Lung Cancer Fall Preview

EP. 1: Overview of Novel Therapy for Advanced-Stage NSCLC

September 6th 2019

EP. 2: Advanced-Stage NSCLC: Overall Survival Data From FLAURA

September 6th 2019

EP. 3: LIBRETTO-001: Targeting RET Fusions in Advanced-Stage NSCLC

September 6th 2019

EP. 4: Updated Data in Stage IV NSCLC: CheckMate-227

September 6th 2019

EP. 5: Metastatic NSCLC: Interpreting Data From NEPTUNE

September 6th 2019

EP. 6: Future Directions in Lung Cancer Management

September 6th 2019

EP. 7: Targeted Therapy for KRAS p.G12C NSCLC

September 6th 2019

EP. 8: Extensive-Stage SCLC: Potential in the CASPIAN Trial

September 6th 2019

EP. 9: Expanding the NSCLC Armamentarium: IMpower131

September 6th 2019

EP. 10: MET as a Clinical Target in Lung Cancer

September 6th 2019

EP. 11: Novel Lung Cancer Therapy: Future Improvements and Challenges

September 6th 2019